VivoSeq
Cardiovascular

Aortic Dissection

12

Pipeline Programs↗

10

Active Trials↗

11

Companies Involved↗

Aortic dissection is an emerging landscape with 12 programs across 11 companies. The most active players are Cellphire Therapeutics, Inc., Javelin Pharmaceuticals, Pfizer. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

27/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cellphire Therapeutics, Inc.

1 program

Phase 2J

Javelin Pharmaceuticals

1 program

Phase 3Pfizer logo

Pfizer

1 program

ApprovedN

Nobilis Therapeutics Inc.

1 program

PreclinicalA

Amring

1 program

PreclinicalS

Shanghai IxCell Biotechnology Co., LTD

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

13 of 14 classified programs — the dominant modality here.

7%ALL OTHERSCell therapy17%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 95% of 19 pipeline programs.

Analysis

Trial Status

23

clinical trials

Unknown status7 · 30%
Completed6 · 26%
Recruiting5 · 22%
Not yet recruiting4 · 17%
Enrolling by invitation1 · 4%

Clinical Trials

Trial Activity

23 trials

Creation of a Digital Twin for Predicting the Progression of Patients With Chronic Thoracic Aortic Dissection
Recruiting·—·N/A·NCT07315178·400 enrolled
Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
Recruiting·NNanjing Medical University·N/A·NCT05339529·330 enrolled
Evaluation of the GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
Recruiting·WW.L.Gore & Associates·Preclinical·NCT06827990·112 enrolled
Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection -A Single-Center, Randomized, Double-Blind, Controlled Clinical Trial
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT06968806·360 enrolled
A Prospective, Multicenter, Randomized Controlled Study to Evaluate the Safety and Efficacy of the WeFlow-EndoSeal™ Aorta Vascular Plug System Combined With TEVAR for the Treatment of Stanford Type B Aortic Dissection
Recruiting·HHangzhou Endonom Medtech Co., Ltd.·Preclinical·NCT07658651·256 enrolled
Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection
Not yet recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT07156656·236 enrolled
Use of PRP in Open Surgery for Type A Aortic Dissection
Not yet recruiting·—·Phase 2/3·NCT07005661·250 enrolled
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
Not yet recruiting·NNanjing Medical University·N/A·NCT07382375·300 enrolled
Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection
Not yet recruiting·FFujian Medical University·N/A·NCT04356300·60 enrolled
Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)
Enrolling by invitation·NNanjing Medical University·N/A·NCT06966687·200 enrolled
Thrombosomes® in Acute Thoracic Aortic Dissections
Completed·JJakob Stensballe, MD, PhD·Phase 2·NCT05771831·41 enrolled
Glucocorticoids for Post-operative Patients With Acute Type A Aortic Dissection (The GLAD Trial)
Completed·SShanghai Zhongshan Hospital·Phase 4·NCT05329740·212 enrolled
Correlation Between Sex and Prognosis of Acute Aortic Dissection in the Chinese Population
Completed·SShenyang Northern Hospital·N/A·NCT03381716·884 enrolled
Prognostic Value of Systemic Immune-Inflammatory and Nutritional Indices for Mortality and Morbidity in Acute Aortic Dissection: A Single-Center Retrospective Study
Completed·BBursa City Hospital·N/A·NCT07683260·127 enrolled
A Retrospective Chart-Review Evaluating Direct Three-Vessel Antegrade Cerebral Perfusion Versus Unilateral Right Axillary Antegrade Cerebral Perfusion in Emergency Total Arch Replacement for Acute Type A Aortic Dissection at CMUH (2021-2025)
Completed·CChina Medical University Hospital·N/A·NCT07043777·201 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)